Mahajan Aatish, Chandran Sivasankar, Kumar Ashok, Chen Ling, Dhillon Navneet K
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Kansas Medical Center.
Arterioscler Thromb Vasc Biol. 2025 Jun 26. doi: 10.1161/ATVBAHA.125.322734.
In this study, we define the mechanistic association between long noncoding RNA: ENST00000495536 (lnc-536) and transcription factor HOXB13 in mediating proproliferative smooth muscle phenotype associated with pulmonary hypertension.
In vitro knockdown or knockin, along with RNA pull-down and immunoprecipitation studies, were used to evaluate the role of lnc-536 and HOXB13 in regulating pulmonary arterial smooth muscle cell (PASMCs) phenotype. The in vivo role was determined by injecting lnc-536 antisense oligos in pulmonary hypertensive rats.
Increased levels of lnc-536 promote the proliferative phenotype of PASMCs by downregulating the expression of the tumor suppressor: HOXB13. Knockdown of lnc-536 and overexpression of HOXB13 in proliferative PASMCs resulted in increased expression of VGLL4, a negative regulator of Hippo and Wnt signaling pathways, with a corresponding decrease in TEAD4 expression. The lnc-536 pull-down assay and RNA-immunoprecipitation demonstrated the interactions of lnc-536 with RBP (RNA-binding protein): RBM25 (RNA-binding motif 25) and direct interactions of RBM25 with SFPQ (splicing factor proline/glutamine-rich), a transcriptional regulator that has a binding motif on HOXB13. The knockdown of RBM25 in the hyperproliferative PASMCs resulted in increased interactions of SFPQ and HOXB13 mRNA while attenuating PASMC proliferation. Furthermore, the increased levels of lnc-536 and decreased levels of HOXB13 were observed in PASMCs from idiopathic pulmonary hypertension patients but not in cells from familial pulmonary hypertension patients. We confirmed that lnc-536 contributes to the RBM25-mediated remodeling of the SFPQ-HOXB13 complex in the idiopathic PAH-PASMCs as well. Finally, in vivo inhibition of lnc-536 using GapmeRs in Sugen-hypoxia and HIV-transgenic pulmonary hypertension rats prevented the increase in right ventricular systolic pressure, right ventricular hypertrophy/fibrosis, and pulmonary vascular remodeling with a parallel increase in HOXB13 expression in rat PASMCs.
Lnc-536 acts as a decoy for RBM25, which in turn sequesters SFPQ, leading to a decrease in HOXB13 expression and hyperproliferation of smooth muscle cells by potentially regulating Wnt and Hippo signaling associated with PAH development.
在本研究中,我们确定了长链非编码RNA:ENST00000495536(lnc - 536)与转录因子HOXB13之间的机制关联,其介导了与肺动脉高压相关的促增殖平滑肌表型。
采用体外敲低或敲入,以及RNA下拉和免疫沉淀研究,以评估lnc - 536和HOXB13在调节肺动脉平滑肌细胞(PASMCs)表型中的作用。通过向肺动脉高压大鼠注射lnc - 536反义寡核苷酸来确定其体内作用。
lnc - 536水平升高通过下调肿瘤抑制因子HOXB13的表达促进PASMCs的增殖表型。在增殖性PASMCs中敲低lnc - 536并过表达HOXB13导致Hippo和Wnt信号通路的负调节因子VGLL4表达增加,而TEAD4表达相应降低。lnc - 536下拉试验和RNA免疫沉淀证明lnc - 536与RNA结合蛋白(RBP):RBM25(RNA结合基序25)相互作用,以及RBM25与SFPQ(富含脯氨酸/谷氨酰胺的剪接因子)直接相互作用,SFPQ是一种在HOXB13上具有结合基序的转录调节因子。在过度增殖的PASMCs中敲低RBM25导致SFPQ与HOXB13 mRNA的相互作用增加,同时减弱PASMCs增殖。此外,在特发性肺动脉高压患者的PASMCs中观察到lnc - 536水平升高和HOXB13水平降低,而在家族性肺动脉高压患者的细胞中未观察到。我们证实lnc - 536也有助于特发性PAH - PASMCs中RBM25介导的SFPQ - HOXB13复合物重塑。最后,在Sugen - 低氧和HIV转基因肺动脉高压大鼠中使用GapmeRs对lnc - 536进行体内抑制,可防止右心室收缩压升高、右心室肥大/纤维化和肺血管重塑,同时大鼠PASMCs中HOXB13表达平行增加。
Lnc - 536作为RBM25的诱饵,进而隔离SFPQ,导致HOXB13表达降低和平滑肌细胞过度增殖,这可能是通过潜在调节与PAH发展相关的Wnt和Hippo信号实现的。